Intelligence Profile
Research Papers
Research Papers and Clinical Trials
The current evidence base for TB-500 (Thymosin Beta-4) is quite limited, consisting primarily of analytical studies and one early-phase clinical trial.
Published Research
The available research focuses mainly on detection and characterization rather than therapeutic efficacy. A 2026 review in Sports Medicine examined the safety and efficacy of various peptide therapies for musculoskeletal injuries and athletic performance, including TB-500, though specific details about study design and sample sizes are not provided in the available evidence.
Two analytical chemistry studies from 2012 focused on TB-500's detection and synthesis. One study published in the Journal of Chromatography developed methods for detecting TB-500 in equine urine and plasma using liquid chromatography-mass spectrometry, reflecting concerns about its potential use as a performance-enhancing substance in sports. A companion study in Drug Testing and Analysis characterized the synthesis of TB-500's active fragment (amino acids 17-23 of thymosin beta-4).
Clinical Trials
Currently, there is one registered clinical trial (NCT07487363) investigating TB-500 for cardiovascular applications. This Phase 1/2 trial is examining TB-500's effects on cardiovascular biomarkers in patients with stable atherosclerotic cardiovascular disease (ASCVD). The trial is listed as recruiting, indicating it is in early stages, and specific enrollment numbers or preliminary results are not yet available.
Evidence Limitations
The research base for TB-500 remains quite thin. Most published work focuses on detection methods rather than clinical effectiveness, and the single clinical trial is still in progress. There is a notable absence of completed randomized controlled trials examining TB-500's therapeutic effects in humans.
This information is for educational purposes only and should not be considered medical advice. Consult healthcare providers for treatment decisions.